NRx Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on March 30, 2023
NRx Pharmaceuticals (Nasdaq: NRXP) will release its Q4 and full year 2022 financial results on March 30, 2023, after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
NRx Pharmaceuticals (Nasdaq: NRXP) will release its Q4 and full year 2022 financial results on March 30, 2023, after market close. A conference call to discuss these results and provide clinical updates is scheduled for 4:30 p.m. ET on the same day. The company is known for developing therapeutics for CNS disorders like suicidal depression and PTSD. Its lead program, NRX-101, is under investigation in a Phase 3 trial with FDA Breakthrough Therapy Designation. This designation recognizes prior trial results showing significant improvement in depression and suicidality.
Positive
- NRX-101 is in a Phase 3 trial with FDA Breakthrough Therapy Designation.
- Previous STABIL-B trial results showed NRX-101 significantly improved depression and suicidality compared to placebo.
Negative
- None.
Details
News Market Reaction – NRXP
The recorded move for NRXP in the trading session of this news was +3.24%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
A live webcast of the conference call will be available on the Company's website at https://ir.nrxpharma.com/news-events/ir-calendar. An archive of the webcast will be available on the Company's website.
Participants that are unable to join the webcast can access the conference call via telephone by dialing domestically +1 (833) 630-1956 or internationally +1 (412) 317-1837.
About
Clinical-stage biopharmaceutical company developing therapeutics for the treatment of central nervous system disorders, specifically suicidal depression and post-traumatic stress disorder (PTSD). The company's lead program NRX-101, an oral, fixed-dose combination of D-cycloserine and lurasidone, targets the brain's NMDA receptor and is being investigated in a Phase 3 trial under an FDA Special Protocol Agreement and Breakthrough Therapy Designation in patients with bipolar depression and suicidal ideation, an indication for which the only approved treatment is electroshock therapy. NRx Pharmaceuticals has also initiated a Phase 2b clinical trial in patients with Sub-Acute Suicidality, a substantially broader indication. The Breakthrough Therapy Designation and Special Protocol Agreement were awarded by the FDA based on the Company's prior STABIL-B trial that demonstrated substantial improvement over available therapy in reducing depression and suicidality compared to placebo when patients were treated with NRX-101 after a single dose of ketamine.
View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-to-report-fourth-quarter-and-full-year-2022-financial-results-on-march-30-2023-301774809.html
SOURCE
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.